Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Role of EGFR SNPs in survival of advanced lung adenocarcinoma patients treated with Gefitinib.

Gene - 15 Mar 2013

Zhang Li, Yuan Xianglin, Chen Yuan, Du Xiao-Juan, Yu Shiying, Yang Ming

Abstract excerpt

AIM: As a novel molecularly targeting agent for non-small-cell lung cancer (NSCLC), Gefitinib can block its tyrosine kinase activity of the epidermal growth factor receptor (EGFR). Genetic variations in EGFR may affect its protein function or expression and lead to diverse outcomes in NSCLC patients after Gefitinib therapy. Therefore, this prospective study examined whether EGFR single nucleotide polymorphisms...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Carcinoma, Non-Small-Cell Lung
Share to ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gefitinib

Share to Neoplasm Staging

Share to Protein Kinase Inhibitors

Share to Quinazolines

Share to Survival Rate

Source

Identifiers

PMID: 23313300
DOI: 10.1016/j.gene.2012.12.087

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026. Manifest publication-graph-cohort-2026-09-05.1.

Source receipt: pubmed, retrieved 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Role of EGFR SNPs in survival of advanced lung adenocarcinoma patients treated with Gefitinib.PMID 23313300Read ↗

Polymorphisms of EGFR predict clinical outcome in advanced non-small-cell lung cancer patients treated with Gefitinib.Semantic proximity Read ↗

EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan.Semantic proximity Read ↗

SNPs in the transforming growth factor-β pathway as predictors of outcome in advanced lung adenocarcinoma with EGFR mutations treated with gefitinib.Semantic proximity Read ↗

Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinibSemantic proximity Read ↗

Prognostic implications of the EGFR polymorphism rs763317 and clinical variables among young Chinese lung cancer population.Semantic proximity Read ↗

Polymorphisms in EGFR and VEGF contribute to non-small-cell lung cancer survival in a Chinese population.Semantic proximity Read ↗

Genetic polymorphism in the epidermal growth factor receptor gene predicts outcome in advanced non-small cell lung cancer patients treated with erlotinib.Semantic proximity Read ↗

Clinical outcomes of advanced non-small cell lung cancer patients screened for epidermal growth factor receptor gene mutations.Semantic proximity Read ↗

Impact of ABCG2 polymorphisms on the clinical outcome of TKIs therapy in Chinese advanced non-small-cell lung cancer patientsSemantic proximity Read ↗

Prognostic implications of genetic variants in advanced non-small cell lung cancer: a genome-wide association study.Semantic proximity Read ↗

Clinical Implications of the Autophagy Core Gene Variations in Advanced Lung Adenocarcinoma Treated with Gefitinib.Semantic proximity Read ↗

Mutation in the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor Is a Predictive and Prognostic Factor for Gefitinib Treatment in Patients with Non–Small Cell Lung CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.